Blueprint Medicines

Food and Drug Administration genehmigt in den USA AYVAKIT™ (Avapritinib) von Blueprint Medicines zur Behandlung von Erwachsenen mit fortgeschrittener systemischer Mastozytose FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis advSM

---

<i class="fa fa-external-link"></i> Zur Website